Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Xequel Bio, a clinical stage biopharmaceutical company whose technology was licensed from the Medical University of South Carolina, is transforming its proprietary aCT1 peptide technology platform to develop drugs that will revolutionize the way the body responds to injury. Led by a proven leadership team, Xequel Bio is poised for its next chapter of success leveraging deep R&D expertise and building on a proprietary platfo...
Xequel Bio, a clinical stage biopharmaceutical company whose technology was licensed from the Medical University of South Carolina, is transforming its proprietary aCT1 peptide technology platform to develop drugs that will revolutionize the way the body responds to injury. Led by a proven leadership team, Xequel Bio is poised for its next chapter of success leveraging deep R&D expertise and building on a proprietary platform with robust commercial potential.

List your booth number for exhibitions, ask us